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Abstract
Background: Hypoventilation due to respiratory insufficiency is the most common cause of death in amyotrophic
lateral sclerosis (ALS) and non-invasive ventilation (NIV) can be used as a palliative treatment. The current guidelines
recommend performing spirometry, and recording nocturnal oxyhemoglobin saturation and arterial blood gas
analysis to assess the severity of the hypoventilation. We examined whether the respiratory rate and thoracic
movement were reliable preliminary clinical signs in the development of respiratory insufficiency in patients with
ALS.
Methods: We measured the respiratory rate and thoracic movement, performed respiratory function tests and
blood gas analysis, and recorded subjective hypoventilation symptoms in 42 ALS patients over a 7-year period. We
recommended NIV if the patient presented with hypoventilation matching the current guidelines. We divided
patients retrospectively into two groups: those to whom NIV was recommended within 6 months of the diagnosis
(Group 1) and those to whom NIV was recommended 6 months after the diagnosis (Group 2). We used the Mann
Whitney U test for comparisons between the two groups.
Results: The mean partial pressure of arterial carbon dioxide in the morning in Group 1 was 6.3 (95% confidence
interval 5.6–6.9) kPa and in Group 2 5.3 (5.0–5.6) kPa (p = 0.007). The mean respiratory rate at the time of diagnosis
in Group 1 was 21 (18–24) breaths per minute and 16 (14–18) breaths per minute in Group 2 (p = 0.005). The mean
thoracic movement was 2.9 (2.2–3.6) cm in Group 1 and 4.0 (3.4–4.8) cm in Group 2 (p = 0.01). We observed no
other differences between the groups.
Conclusions: Patients who received NIV within six months of the diagnosis of ALS had higher respiratory rates and
smaller thoracic movement compared with patients who received NIV later. Further studies with larger numbers of
patients are needed to establish if these measurements can be used as a marker of hypoventilation in ALS.
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Background
Amyotrophic lateral sclerosis (ALS) is a form of degen-
erative motor neuron disease of unknown etiology. The
disease is characterized by progressive muscle weakness
and atrophy throughout the body [1-3]. The prevalence
is 4–8 in 100 000 and the annual incidence is 1–2 in 100
000 [4]. Prognosis is poor with a median survival from the
onset of symptoms of 2–4 years [5,6]. Despite extensive
effort, no curative treatment is available and riluzole
(a tetrodotoxin-sensitive sodium channel blocker) is the
only drug that can slow the progression of the disease
[7,8]. Therefore, treatment following the diagnosis is
palliative [9,10].
Hypoventilation due to respiratory insufficiency is the
most common cause of death in patients with advanced
ALS [3,5]. Non-invasive ventilation (NIV) has been
recommended for ALS patients when hypoventilation
occurs because it relieves dyspnoea, increases the quality
of life, and may prolong survival in late stage ALS
patients [11-13]. The current guidelines recommend
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beginning NIV if the patient presents with dyspnoea,
orthopnoea, disturbed sleep, tachypnoea, nocturnal de-
saturation < 90%, increased morning carbon dioxide par-
tial pressure (pCO2) > 6 kPa, decreased sniff nasal
pressure < 40 cmH2O, decreased maximum inspiratory
mouth pressure (MIP) < 60 cmH2O, or decreased forced
vital capacity (FVC) < 80% [9,10,14]. However, there is
great international variation in the use of different diag-
nostic tests prior to initiation of NIV.
The onset of muscle weakness varies between patients
and symptoms may appear first in the limbs or they may
start from the bulbar area leading to dysphagia and
speech difficulties [3]. This wide variability in the clinical
course of ALS can be challenging for the clinician be-
cause the progression of respiratory insufficiency also
greatly varies among these patients [1,3]. Because of this
variability, the current guidelines recommend a clinical
visit every 2–3 months [9,10]. Although nocturnal desat-
uration and carbon dioxide tension can be recorded
noninvasively, it is often not possible to perform these
measurements outside the hospital because of lack of
devices and health care providers to assist the patient.
The measurement of increased morning pCO2 requires
blood sampling by a health care professional. In addition,
spirometric measurements require good facial function,
as patients have to hold their lips tightly around the
mouthpiece of the spirometer. In ALS patients with
severe bulbar dysfunction, this measurement may be
unreliable [10,15]. We therefore wished to determine if
we could use respiratory rate and thoracic movement as




This study was a retrospective register study. According
to Finnish legislation, patient consent is not required
for register studies in Finland. The study protocol was
approved by the ethics committee of the Hospital District
of South-West Finland. The data were collected as part of
routine measurements in patients diagnosed with ALS at
the Turku University Hospital during January 2005 to
March 2012. A total of 77 patients fulfilled the El Escorial
World Federation criteria for ALS [16]. NIV treatment
and other palliative treatments were offered to all the
patients. The respiratory measurements were obtained
within three months of the diagnosis in only 42 patients
who were included in the per-protocol analysis of the data.
Twenty-nine patients were excluded because respiratory
measurements were not performed within the three-
month period from the diagnosis. The three-month time
window was assumed to reflect the respiratory function of
the patients at the time of the ALS diagnosis. We excluded
an additional three patients because of lack of cooperation
(frontotemporal dementia) and three patients declined
follow-up for NIV. Although NIV was recommended for
42 patients, 29 of these 42 patients were able to use NIV.
Based on earlier studies [5,6] in which the course of the
disease was rapid, we divided these 42 patients retrospect-
ively into two groups: those for whom NIV was recom-
mended within 6 months from the diagnosis (Group 1;
n = 22) and those for whom NIV was recommended after
6 months from the diagnosis (Group 2; n = 20) (Figure 1).
Before the NIV trial, we asked the patients if they were
willing to start the treatment. Each patient made the final
decision whether to begin NIV.
Data collection
The patients were referred to the Department of Pulmon-
ary Diseases, following diagnosis of ALS by a neurologist.
An experienced respiratory physiotherapist performed the
respiratory function tests. The respiratory rate was
assessed before any other measurements with the patient
awake, in a supine position and following a one-hour rest.
A specialized nurse observed and calculated the respira-
tory rate during one minute. We measured forced vital
capacity (FVC) and forced expiratory volume exhaled in
1s (FEV 1) using a hand-held MicroPlusW spirometer
(Cardinal Health, Chatham, UK), and expressed each as a
fraction of the predicted values in per cent [17]. Respira-
tory muscle tests included assessments of peak cough flow
(PCF), maximum inspiratory mouth pressure (MIP), max-
imum expiratory mouth pressure (MEP), and sniff nasal
pressure (SNP), all measured with MicroRPMW (Cardinal
Health, Chatham, UK). We performed each measurement
three times with the patient in a sitting position and sub-
mitted the best value for the analyses. We measured the
thoracic movement at the mammillary level with the pa-
tient in a sitting position and recorded the difference in
the thoracic circumference between the maximal inspir-
ation and expiration. The respiratory rate was expressed
as breaths per min (BPM) at rest. An arterial blood gas
sample was drawn from the radial artery in the morning
just after waking and with the patient in a supine position.
We assessed the subjective symptoms of hypoventilation
using a set of visual analogue scales (VAS) using a 10 cm
long line with opposite extremes at each end, where 0
indicated no symptoms and 10 indicated the worst im-
aginable symptoms; assessing dyspnoea, cough weakness,
sleep disturbances, morning headaches, and daytime
sleepiness. If a patient was not able to tick the line on the
VAS because of impaired motor function of his/her hand,
the physiotherapist marked the patient’s response.
Ventilatory support
NIV was provided using a pressure-targeted ventilator
(VPAP III STW, ResMed, Bella Vista, Australia). Both a
pulmonologist and an anaesthesiologist assessed the
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need for NIV. The primary criteria for recommendation
for an NIV trial were dyspnoea at rest, increased pCO2 >
5.5 kPa or decreased pO2 < 10 kPa in the morning arter-
ial blood gases or decreased FVC under 50% of the pre-
dicted value. The secondary criteria for recommendation
for an NIV trial were MIP < 60 cmH2O, or SNP < 40
cmH2O. We interpreted a VAS score > 5 for dyspnoea as
an indication to recommend an NIV trial. The remain-
ders of the measurements were used as supportive
criteria to recommend an NIV trial.
Statistical analyses
The results are shown as mean with a 95% confidence
interval unless otherwise stated. We used the Mann
Whitney U test for comparisons between the two groups
at the time of the diagnosis. P values < 0.05 were consid-
ered statistically significant. We used GraphPad Prism
Software, Version 5.00 (San Diego, California, USA) for
the statistical calculations.
Results
The records for 42 patients with ALS (20 male, 22 female)
were adequate for analysis. The characteristics of the
patients are shown in Table 1. The age and the duration of
the symptoms before the diagnosis of ALS did not differ
between the groups.
The mean pCO2 and pO2 in the morning arterial
blood gas samples at the time of diagnosis in Group 1
were 6.3 (5.6–6.9) and 9.8 (9.3–10.4) kPa, respectively.
The mean pCO2 and pO2 at the time of diagnosis in
Group 2 were 5.3 (5.0–5.6) and 10.7 (9.4–12) kPa, re-
spectively. The mean pCO2 was significantly higher in
Group 1 (p = 0.007) whereas the values for mean pO2
did not differ between the two groups (p = 0.4). The
mean respiratory rate at the time of diagnosis in Group
1 was 21 (18–24) BPM and 16 (14–18) BPM in Group 2
(p = 0.005). The mean thoracic movement at the time
of diagnosis in Group 1 was 2.9 (2.2–3.6) cm and 4.0
(3.4–4.8) cm in Group 2 (p = 0.01). We observed no
other differences between the two groups (Table 2).
Discussion
This was a retrospective study to clarify if we could use
the respiratory rate and thoracic movement as prelimin-
ary clinical signs for the development of significant re-
spiratory insufficiency in ALS patients. The main finding
in our study was that patients who received NIV within
six months of the diagnosis of ALS had higher respiratory
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Figure 1 Study flow chart.
Table 1 Patient characteristics
Group 1 (n=22) Group 2 (n=20)
Median Range Median Range p
Age at diagnosis (years) 69 49–83 69 54–85 0.9
Duration from the first symptoms to diagnosis (months) 11 1–48 13 3–60 0.8
Duration from the diagnosis to initiation of NIV (months) 2 0–5 12 6–29 < 0.001
The difference between the groups was assessed using the Mann Whitney U test.
NIV = non-invasive ventilation.
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rates and smaller thoracic movement at diagnosis com-
pared with patients who received NIV later.
Among healthy subjects, a respiratory rate under 15
BPM allows a physiologically optimal level of work of
breathing [18,19]. In advanced ALS, thoracic compliance
is usually decreased, resulting in decreased tidal volume
[20], increased respiratory rate and work of breathing
[18,19]. NIV can help patients compensate for the
decreased thoracic compliance and thus decrease the re-
spiratory frequency and the work of breathing [20,21].
Although the retrospective study design and small num-
ber of patients did not allow the calculation of positive
and negative predictive values and cut-off values for re-
spiratory rate and thoracic movement in the assessment
of respiratory insufficiency in ALS, it appears that NIV
was initiated within six months from diagnosis for those
patients who had a respiratory rate at least of 20 BPM at
the moment of diagnosis.
Another result of interest was that we failed to show
any difference in dyspnoea between the two study
groups (Table 2). The patients scored only mild symp-
toms of dyspnoea and morning headaches at the
moment of diagnosis in both groups. The same was true
for sleep disturbances and daytime sleepiness. In a previ-
ous study with 36 ALS patients, respiratory complaints
did not occur until the vital capacity, MIP, or MEP were
severely impaired [22]. In that study, the strongest cor-
relation with dyspnoea was a decline in vital capacity.
The authors suggested that a small reduction in vital
capacity does not cause any symptoms except in heavy
exercise. The patients decrease their physical activity be-
cause of skeletal muscle weakness, and thus may not feel
dyspnoeic during their daily activities unless more
strenuous exercise is required. Our results are similar as
our patients complained of very little dyspnoea at the
time of diagnosis. Nevertheless, as our patients were
aware of the possibility of initiating NIV, they might
have been reluctant to disclose the severity of their
symptoms and intentionally underestimated their re-
sponse in our VAS query. A larger sample size might
show a difference in dyspnoea.
FVC and FEV 1 are commonly used to assess pulmon-
ary function in lung diseases [23] and in ALS patients.
Previously, FVC, SNP, MIP and MEP were determined
Table 2 Respiratory function tests, blood-gas analysis and subjective symptoms at the time of diagnosis
Group 1 Group 2
Measurement Mean (95% CI) n Mean (95% CI) n p*
Lung function tests
FVC (%) 58 (44–72) 20 69 (58–74) 20 0.4
FEV 1/s (%) 59 (46–72) 20 69 (61–72) 20 0.2
Respiratory muscle force
MIP (cmH2O) 29 (20–39) 21 48 (30– 65) 20 0.07
MEP (cmH2O) 40 (28–52) 21 60 (42–78) 20 0.07
SNP (cmH2O) 24 (9–40) 18 31 (21–41) 18 0.1
PCF (l/min) 240 (180–300) 18 310 (250–370) 20 0.1
Severity of hypoventilation symptoms
Dyspnoea 4 (3–6) 21 2 (1–3) 20 0.05
Cough weakness 3 (2–5) 21 3 (1–4) 20 0.4
Sleep disturbance 5 (3–6) 21 3 (2–3) 20 0.05
Morning headaches 2 (0–3) 21 1 (0–2) 20 0.7
Daytime sleepiness 4 (3–6) 21 4 (2–5) 20 0.4
Thoracic movement (cm) 2.9 (2.2–3.6) 22 4.0 (3.4–4.8) 20 0.01
Respiratory rate (breaths/min) 21 (18–24) 22 16 (14–18) 20 0.005
Arterial blood-gas analysis
pCO2 (kPa) 6.3 (5.6–6.9) 17 5.3 (5.0–5.6) 12 0.007
pO2 (kPa) 9.8 (9.3–10.4) 17 10.7 (9.4–12) 12 0.4
*Determined using the Mann Whitney U test.
n = number of patients completing the measurement; CI = confidence interval; FVC = forced vital capacity expressed as % from the reference values; FEV 1 =
forced expiratory volume exhaled in one second and expressed as % from the reference values; MIP = maximal inspiratory mouth pressure; MEP = maximal
expiratory mouth pressure; SNP = sniff nasal pressure; PCF = peak cough flow. All measurements were performed three times in a sitting position and the best
values were recorded.
The severity of hypoventilation symptoms was assessed using a visual analogue scale (VAS) in which 0 represented no symptoms and 10 represented the worst
symptoms that the patients could imagine. Thoracic movement was measured using a measuring tape and recorded as the difference in the thoracic
circumference during maximal inspiration and expiration at the mammillary level.
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in 16 ALS patients monthly over a period of 18 ± 10
months [24]. The SNP, MIP and MEP were severely
reduced even though the FVC remained normal. In
addition, the measurement of MIP and MEP was diffi-
cult in these advanced ALS patients because they had
difficulties tightly holding the mouthpiece of the record-
ing device. This led to air leaks and reduced the values
of MIP and MEP. A reduced SNP of under 40 cmH2O
has been suggested as the most sensitive and easiest test
to perform in ALS patients [9,10,24]. However, although
we found that the SNP was severely reduced in both
groups, only those with an increased respiratory rate in
Group 1 were ready to start NIV (Table 2).
Our study has limitations. First, the retrospective de-
sign compared the respiratory measurements between
two different patient groups at one single time point.
Thus, we cannot draw definitive conclusions for the cut-
off values for respiratory rate or thoracic movement to
indicate the need for NIV. Further studies are needed. In
addition, the only inclusion criterion was the respiratory
assessment within three months from diagnosis. Thus,
we did not evaluate other pulmonary or heart diseases
which might have biased the results. Second, the ideal is
a randomized prospective trial in which the initiation of
NIV is blinded and the subjects are observed from an
asymptomatic stage until severe hypoventilation occurs.
However, because NIV is established in palliative care in
ALS [9,10], ethical aspects have to be considered in ran-
domized study designs, especially if the initiation of NIV
is somehow blinded. Moreover, the diagnosis of ALS is
often delayed and the patients often have reduced venti-
lation capacity at the time of diagnosis [22,25]. We saw
this in our patients as the median time from the first
symptoms until diagnosis ranged from 11 to 13 months
(Table 1). During this time, the patients’ symptoms were
evaluated at the primary care level or not at all. Thus,
when we met the patients, half already showed moder-
ately to severely reduced FVC (60%), SNP (24 cmH2O),
MIP (29 cmH2O), or MEP (41 cmH2O) and NIV was
recommended based on a single measurement without
follow-up. Third, we dealt with severely ill patients,
whose NIV initiation was based on both the clinical
measurements and the patient’s own desire. The fact
that NIV was based on the patient’s own desire may
have biased the answers in the hypoventilation question-
naire if the patients reported no or only mild symptoms
of hypoventilation even if they had severely reduced
respiratory measurements.
Conclusions
The use of NIV as palliative treatment has previously
been shown to relieve symptoms as well as to improve
survival in ALS patients [11-13]. However, the optimal
timing for initiating NIV is not yet well established.
Most of the available methods used to evaluate the de-
gree of hypoventilation and the need for NIV require
well-trained health care professional and special devices.
In contrast, assessing resting respiratory rate or thoracic
movement can be performed in a patient’s home by pri-
mary care nursing staff and could be a feasible screening
tool for detecting hypoventilation. However, further
studies are needed to define the positive and negative
predictive values and cut-off values for respiratory rate
and thoracic movement in the assessment of respiratory
insufficiency in ALS.
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